Relmada Therapeutics, Inc. SEC filings RLMD
Relmada Therapeutics, Inc. has 606 filings in SEC EDGAR's recent list, going back to Nov 13, 2012. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jun 18, 2026 | — |
| S-3ASR | Automatic shelf registration | May 13, 2026 | — |
| 424B3 | Prospectus | Apr 9, 2026 | — |
| S-3 | Shelf registration | Apr 3, 2026 | — |
| 424B5 | Prospectus supplement | Jan 30, 2026 | — |
| 424B5 | Prospectus supplement | Nov 5, 2025 | — |
| FWP | Free writing prospectus | Nov 4, 2025 | — |
| S-8 | Employee stock plan registration | Jun 13, 2025 | — |
| 424B5 | Prospectus supplement | Apr 28, 2025 | — |
| S-3 | Shelf registration | Aug 30, 2024 | — |
| S-8 | Employee stock plan registration | Jun 21, 2023 | — |
| S-3ASR | Automatic shelf registration | Apr 7, 2022 | — |
| 424B5 | Prospectus supplement | Dec 10, 2021 | — |
| 424B5 | Prospectus supplement | Dec 8, 2021 | — |
| S-8 | Employee stock plan registration | Jul 6, 2021 | — |
| S-3 | Shelf registration | Aug 12, 2020 | — |
| 424B5 | Prospectus supplement | May 15, 2020 | — |
| 424B5 | Prospectus supplement | Dec 5, 2019 | — |
| 424B5 | Prospectus supplement | Dec 3, 2019 | — |
| 424B3 | Prospectus | Nov 1, 2019 | — |
| S-3/A | Amendment no. 1 to form s-3 | Oct 28, 2019 | — |
| POS AM | Registration statement | Oct 25, 2019 | — |
| 424B3 | Prospectus | Oct 24, 2019 | — |
| S-3 | Shelf registration | Oct 18, 2019 | — |
| S-1/A | Amended registration statement | Oct 17, 2019 | — |
| S-1/A | Amended registration statement | Oct 11, 2019 | — |
| S-1 | Registration statement | Aug 12, 2019 | — |
| S-8 | Employee stock plan registration | May 15, 2019 | — |
| 424B3 | Prospectus | Mar 5, 2019 | — |
| S-1/A | Amended registration statement | Feb 26, 2019 | — |
| S-1 | Registration statement | Jan 14, 2019 | — |
| S-3/A | Amendment no. 1 to form s-3 | Oct 23, 2018 | — |
| S-8 | Employee stock plan registration | May 14, 2018 | — |
| S-8 | Employee stock plan registration | Oct 2, 2015 | — |
| S-3 | Shelf registration | Oct 2, 2015 | — |
| 424B3 | Prospectus | Dec 31, 2014 | — |
| S-1/A | Amended registration statement | Dec 9, 2014 | — |
| S-1/A | Amended registration statement | Nov 17, 2014 | — |
| S-1/A | Amended registration statement | Oct 16, 2014 | — |
| S-1/A | Amended registration statement | Sep 16, 2014 | — |
| S-1 | Registration statement | Jun 27, 2014 | — |
| 424B3 | Prospectus | May 6, 2013 | — |
| S-1/A | Amended registration statement | Mar 7, 2013 | — |
| S-1/A | Amended registration statement | Feb 26, 2013 | — |
| S-1/A | Amended registration statement | Feb 15, 2013 | — |
| S-1/A | Amended registration statement | Jan 25, 2013 | — |
| S-1 | Registration statement | Nov 13, 2012 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Coral Gables, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553643
- Former names
- CAMP NINE, INC. (until Jul 14, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.